ESR1 and breast neoplasm: Christine Desmedt  from KU Leuven, Belgium, and colleagues found that 9% of patients had metastases with ESR1 mutations that were absent in primary breast tumors; another 6% had mutations in the primary tumors or in cancer-invaded lymph nodes that were not detected in distant metastatic sites.